Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wahid, Faisal
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation	Completed	4	339	US	Dronedarone, Multaq	American Heart Association, Duke Clinical Research Institute, Sanofi	Atrial Fibrillation	01/24	06/24
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	Active, not recruiting	2	456	Europe, Canada, Japan, US, RoW	LY3540378, Placebo	Eli Lilly and Company	Heart Failure, Heart Failure With Preserved Ejection Fraction	01/25	01/25
Shafiq, Hina
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation	Completed	4	339	US	Dronedarone, Multaq	American Heart Association, Duke Clinical Research Institute, Sanofi	Atrial Fibrillation	01/24	06/24